Ebenbuild’s Twinhale technology, a software for creating digital lung twins, was used in a preclinical study on idiopathic pulmonary fibrosis (IPF) published in •Nature Communications•. The study explored the effectiveness of an inhaled therapeutic, PRS-220, developed by Pavella Therapeutics (formerly Pieris Pharmaceuticals), showing promising results for targeted drug delivery in IPF-affected lungs. The research leveraged CT scan data and physiological information to build personalized lung models, simulating drug distribution in both healthy and diseased lungs.
This research is crucial for advancing IPF treatment. Current therapies often struggle to effectively reach and penetrate the scarred lung tissue characteristic of IPF. This study demonstrates the potential of inhaled therapies like PRS-220 to improve drug delivery directly to the affected areas, offering a more targeted and potentially more effective approach. This precision could lead to better treatment outcomes and a higher quality of life for IPF patients, who currently face limited treatment options.
Ebenbuild’s Twinhale technology utilized patient-specific CT scan data from the Open Source Imaging Consortium (OSIC) database. The software created digital twin models of lungs, incorporating factors like lung function and the presence of fibrotic tissue. Simulations using these models demonstrated the superior distribution and penetration of the inhaled PRS-220 into fibrotic lung tissue compared to what might be expected with systemic treatments. This targeted delivery could minimize potential side effects and improve therapeutic efficacy.
This study marks a significant step forward in personalized medicine for respiratory diseases. The ability to create patient-specific lung models and simulate drug delivery holds immense potential for optimizing treatment strategies in IPF and other lung conditions. This technology could accelerate drug development, reduce the need for extensive clinical trials, and ultimately lead to more effective and personalized therapies for patients with respiratory illnesses.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
